Edward Rosfjord

机构：Pfizer (United States), AstraZeneca (Japan), AstraZeneca (United States) · ORCID：0000-0002-3449-7444

发表论文 184 篇 · 总被引 2832 次 · h-index 24

代表论文

• Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers (2025 · Clinical Cancer Research · 被引 3)
• Supplementary Figure S1 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers (2025)
• Supplementary Figure S6 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers (2025)
• Supplementary Table S1 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers (2025)
• Supplementary Table S3 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers (2025)
• Supplementary Figure S2 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers (2025)